Department of Defense
Armed Forces Health Surveillance Branch
Global MERS-CoV Surveillance Summary
(28 JAN 2016)

APPROVED FOR PUBLIC RELEASE

For questions or comments, please contact:
dha.ncr.health-surv.list.afhs-ib-alert-response@mail.mil
DEPARTMENT OF DEFENSE (AFHSB)
Global MERS-CoV Surveillance Summary #75
28 JAN 2016 (next Summary 10 FEB)

CASE REPORT: As of 28 JAN 2016, 1,716 (+8) cases of Middle East respiratory syndrome coronavirus (MERS-CoV) have been reported, including 643 (+1) deaths, in the Kingdom of Saudi Arabia (KSA) (+5), Jordan, Qatar, United Arab Emirates (UAE) (+2), United Kingdom (UK), France, Germany, Tunisia, Italy, Oman, Kuwait, Yemen, Malaysia, Greece, Philippines, Egypt, Lebanon, Netherlands, Iran, Algeria, Austria, Turkey, Republic of Korea (ROK), China, Thailand (+1), and the U.S. All suspect cases previously reported by AFHSB in Hong Kong and Turkey have either been ruled out by laboratory testing or have passed the incubation period with no symptoms. On 25 JAN, the Thailand Ministry of Health (MOH) reported its second case of MERS-CoV (the first was reported in JUN 2015) in a traveler from Oman seeking medical care in Thailand, a common practice among Middle East residents. This case traveled, against medical advice, from Muscat to Bangkok on 22 JAN and is receiving treatment at Chulalongkorn Hospital. At least 352 contacts have been identified (including one accompanying relative, flight passengers, a taxi driver, and hotel staff) of which 28 are considered “high-risk” and are currently quarantined. The fatal UAE case announced on 14 JAN also had recent travel to Oman; the second UAE case was asymptomatic and identified through contact tracing.

DOD RELEVANCE: On 13 NOV 2015, GeneOne Life Science, Inovio Pharmaceuticals, and Walter Reed Army Institute of Research (WRAIR) announced a partnership to create a MERS-CoV vaccine. The Deputy Commander of Operations at WRAIR voiced his support for this partnership as “U.S. military personnel could be at risk in the event of a large scale MERS-CoV outbreak” and noted the clinical trials will be conducted at the WRAIR Clinical Trials Center.

DIAGNOSTICS: Clinical diagnostic testing is available at BAACH, NAMRU-3, LRMC, MAMC, NHRC, USAFSAM, SAMMC, TMC, WBAMC, WRNMMC, and NIDDL (NMRC). Tripler AMC (TAMC) completed validation of clinical diagnostic testing capability on 24 NOV 2015. Surveillance testing capability is available at NHRC, AFRIMS, NAMRU-2, NAMRU-3, NAMRU-6, USAMRU-K, and Camp Arifjan. All 50 state health laboratories and the NYC DOHMH were offered clinical testing kits. On 16 JUL 2015, AFHSB updated MERS-CoV testing guidelines for DoD, which include lab contact information, and are aimed at capturing mild cases that may present in healthier populations such as DoD personnel. On 8 DEC 2015, CDC updated its Interim Patient Under Investigation (PUI) Guidance and Case Definitions for MERS-CoV. Notable changes include: removing references to ROK, clarifying that fever may not be present in some patients, and revising the guidance for testing a PUI.

INTERAGENCY/GLOBAL ACTIONS: On 11-14 JAN 2016, WHO led a joint mission to KSA to review the MERS-CoV situation in the country, assess progress in implementing previous WHO recommendations, identify gaps in research, and agree on a joint operation plan for controlling MERS-CoV. This is the third such mission led by WHO - the previous two occurred in FEB and AUG 2015. The mission concluded that while KSA has made progress in being “more responsive” to acute events, such as repeated nosocomial outbreaks, more still needs to be done. WHO recommendations include: progressing from a passive to an active sentinel surveillance system, moving from planning stages to implementing stages for camel surveillance, not just collaborating between health and agriculture industries but conducting case investigations jointly, and more broadly sharing lessons learned from nosocomial outbreaks outside of insular hospital systems. WHO convened the Tenth International Health Regulations (IHR) Emergency Committee on 2 SEP 2015 and concluded the conditions for a Public Health Emergency of International Concern (PHEIC) have not yet been met. However, the Committee also emphasized that they have a heightened sense of concern as transmission from camels to humans continues in some countries and instances of human-to-human transmission continue to occur in health care settings. The Committee further noted that its advice has not been completely followed as asymptomatic cases that have tested positive for the virus are not always being reported as required. CDC maintains their Travel Alert Level 2 for MERS-CoV in the Arabian Peninsula.

BACKGROUND: In SEP 2012, WHO reported two cases of a novel coronavirus (now known as MERS-CoV) from separate individuals - one with travel history to the KSA and Qatar and one in a KSA citizen. This was the sixth strain of human coronavirus identified (including SARS). Limited human-to-human transmission has been identified in at least 35 spatial clusters predominately involving close contacts. Limited camel-to-human transmission of MERS-CoV has been proven to occur. The most recent known date of symptom onset is 3 JAN 2016, however the Thailand case is believed to have had symptom onset in late JAN 2016. The KSA MOH has previously admitted to inconsistent reporting of asymptomatic cases. Due to these inconsistencies, it is also difficult to determine a cumulative breakdown by gender; however, AFHSB is aware of at least 494 (+1) cases in females to date. CDC reports 288 of the total cases have been identified as healthcare workers (HCWs). Of these, 178 were from KSA, 31 from UAE, 7 from Jordan, 2 from Iran, 1 from Tunisia, and 29 from ROK.

Text updated from the previous report will be printed in red; items in (xxx) represent the change in number from the previous Summary (13 JAN 2016).
All information has been verified unless noted otherwise. Sources include U.S. CDC, WHO, USFK, and the KSA MOH.
For questions or comments, please contact: dha.ncr.health-surv.list.afhs-ib-alert-response@mail.mil
APPROVED FOR PUBLIC RELEASE
Global Distribution of Reported MERS-CoV Cases*
(SEP 2012–JAN 2016)

*KData includes confirmed, suspect and probable cases reported by WHO, CDC, and various country MOHs
*186 cases have been reported in the Kingdom of Saudi Arabia without specific location information.

For questions or comments, please contact: dha.ncr.health-surv.list.afhs-ib-alert-response@mail.mil

Geographic Distribution of MERS-CoV Cases
1 APR 2012 - 28 JAN 2016

**Total Cases N = 1,716**
- 1 - 10
- 11 - 20
- 21 - 75
- 76 - 150
- 151 - 300
- >300
Global MERS-CoV Epidemiological Curve - 28 JAN 2016

Cases  N = 1,716
Deaths  N = 643
### GLOBAL MERS-CoV NUMBERS AT A GLANCE

<table>
<thead>
<tr>
<th></th>
<th>Total in 2012</th>
<th>Total in 2013</th>
<th>Total in 2014</th>
<th>Total in 2015</th>
<th>Total in 2016</th>
<th>Cumulative Total (2012-2016)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cases</strong></td>
<td>9</td>
<td>171</td>
<td>777</td>
<td>747 (+1) cases</td>
<td>9 (+7) cases</td>
<td>1,716 (+8) cases</td>
</tr>
<tr>
<td><strong>Deaths</strong>*</td>
<td>6 deaths</td>
<td>72 deaths</td>
<td>277 deaths</td>
<td>288 (+1) deaths</td>
<td>0 deaths</td>
<td>at least 643 (+1) deaths</td>
</tr>
<tr>
<td><strong>Case-Fatality Proportion</strong></td>
<td>66%</td>
<td>42%</td>
<td>36%</td>
<td>39%</td>
<td>0%</td>
<td>37%</td>
</tr>
<tr>
<td><strong>Mean Age</strong></td>
<td>45 years</td>
<td>51 years</td>
<td>49 years</td>
<td>55 years</td>
<td>61 years</td>
<td>52 years</td>
</tr>
<tr>
<td><strong>Gender Breakdown</strong>*</td>
<td>1 female</td>
<td>at least 58 females</td>
<td>at least 175 females</td>
<td>259 females</td>
<td>1 (+1) females</td>
<td>at least 494 (+1) females</td>
</tr>
<tr>
<td><strong># of Healthcare Workers (HCWs) reported</strong>*</td>
<td>at least 2 HCWs</td>
<td>at least 31 HCWs</td>
<td>at least 87 HCWs</td>
<td>109 HCWs</td>
<td>0 HCWs</td>
<td>at least 288 HCWs</td>
</tr>
</tbody>
</table>

*Disclaimer: Data reported on MERS-CoV cases are limited and adapted from multiple sources including various Ministries of Health, CDC, and WHO. Consequently, yearly information may not equate to the cumulative totals provided by WHO and CDC.

Legend: Text updated from the previous report will be printed in red; items in (+xx) represent the change in number from the previous Summary (13 JAN 2016). For questions or comments, please contact: dha.ncr.health-surv.list.afhs-ib-alert-response@mail.mil

APPROVED FOR PUBLIC RELEASE
MERS-CoV Web Sites

- WHO
- WHO Lab Testing Guidance
- WHO Travel Advice for Pilgrimages
- WHO 10th IHR Meeting Press Release
- CDC
- CDC Travel Advisory for the Arabian Peninsula
- CDC Travel Advisory for ROK
- CDC MMWR
- CDC Interim PUI Guidance
- ECDC
- AFHSB Detecting and Reporting Guidelines for MERS-CoV

Information and News

- Exportations of Symptomatic Cases of MERS-CoV Infection to Countries outside the Middle East (CDC EID, APR 2016)
- Patient travelled to Thailand against advice: MoH (Muscat Daily, 27 JAN)
- Mers patient fever-free, but 12 high-risk contacts gone (Bangkok Post, 27 JAN)
- Latest WHO DON on MERS-CoV in UAE (WHO, 26 JAN)
- Thailand reports imported MERS case; Saudi Arabia notes 2 (CIDRAP, 25 JAN)
- Stay away from young camels (Arab News, 18 JAN)
- The recent ancestry of Middle East respiratory syndrome coronavirus in Korea has been shaped by recombination (Nature, 6 JAN)
- WHO’s high-level mission to Saudi Arabia on Middle East respiratory syndrome coronavirus (MERS-CoV) 11–14 January 2016 (WHO, JAN 2016)
- An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels (Science, 1 JAN)
- Multifacility Outbreak of Middle East Respiratory Syndrome in Taif, Saudi Arabia (CDC EID, JAN 2016)
- Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia (Science, 17 DEC 2015)
- Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Nigeria, 2015 (Eurosurveillance, 10 DEC 2015)
- Researchers Create a Mouse that Can Get MERS (MD Magazine, 8 OCT 2015)
- MERS coronavirus: Candidate vaccine gears up for clinical (EurekAlert, 22 JUN 2015)
- Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study (Lancet, 5 MAY 2015)
- WHO DON on first novel coronavirus infection (WHO, 23 SEP 2012)